Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Inventiva currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed across 3 distinct examiners, which means that every single pending matter is being reviewed by a different individual. The 1 distinct art unit involved indicates that the company's intellectual property is concentrated within a single specialized examination group, providing a consistent procedural environment for the portfolio.
Among the active personnel, Braun, Madeline E is identified as the busiest examiner, currently overseeing 1 of the pending office actions. This assignment of 1 action to each examiner, including Braun, Madeline E, highlights a completely decentralized prosecution environment for the portfolio. For a practitioner, the presence of 3 pending office actions within 1 distinct art unit simplifies the coordination of prosecution efforts, as all cases are subject to the same art unit guidelines.
The fact that 3 distinct examiners are handling 3 pending office actions implies that no institutional knowledge gained from one prosecution will carry over to others through examiner overlap. This lack of overlap, where Braun, Madeline E and all other examiners manage only 1 pending action, means that individual examiner preferences will dictate the outcome of every case. Consequently, the 3 pending office actions represent a landscape where practitioners must engage with 3 different individuals within the same 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| DUNN, MCKENZIE A | 1 | 53.8% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19556476 | METHOD OF MAKING LANIFIBRANOR | BRAUN, MADELINE E | — |
| 18735373 | NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT | DUNN, MCKENZIE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19556476 | METHOD OF MAKING LANIFIBRANOR | BRAUN, MADELINE E | — |
| 18854287 | CRYSTALLINE FORM OF LANIFIBRANOR | KIFLE, BRUCK | — |
| 18735373 | NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT | DUNN, MCKENZIE A | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19556476 | METHOD OF MAKING LANIFIBRANOR | BRAUN, MADELINE E | 1624 | §103§112 | Non-Final OA | — | Pending | Mar 04, 2026 |
| 18854287 | CRYSTALLINE FORM OF LANIFIBRANOR | KIFLE, BRUCK | — | — | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18735373 | NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT | DUNN, MCKENZIE A | — | §101 | Non-Final OA | — | Pending | Jun 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial